Matsubayashi Hiroyuki, Oishi Takuma, Sasaki Keiko, Abe Masato, Kiyozumi Yoshimi, Higashigawa Satomi, Niiya Fumitaka, Sato Junya, Ishiwatari Hirotoshi, Imai Kenichiro, Hotta Kinichi, Kishida Yoshihiro, Takada Kazunori, Ono Hiroyuki, Yamazaki Kenichiro, Yasui Hirofumi, Kenmotsu Hirotsugu, Kado Nobuhiro, Kagawa Hiroyasu, Shiomi Akio, Sugiura Teichi, Bando Etsuro, Nishimura Seiichiro, Hatakeyama Keiichi, Serizawa Masakuni, Harada Rina, Sugino Takashi
Division of Genetic Medicine Promotion, Shizuoka, 411-8777, Japan; Division of Endoscopy, Shizuoka, 411-8777, Japan.
Division of Pathology, Shizuoka, 411-8777, Japan.
Hum Pathol. 2023 May;135:54-64. doi: 10.1016/j.humpath.2022.12.016. Epub 2022 Dec 31.
Microsatellite instability (MSI) and deficiency of mismatch repair (dMMR) are key markers for predicting the response of immune checkpoint inhibitors (ICIs) and screening for Lynch syndrome (LS). This study examined the incidences of and factors associated with the concordance of MSI and MMR in human cancers. A total of 518 formalin-fixed cancer tissues were analyzed for MSI and MMR immunohistochemistry (IHC). MSI was analyzed by a PCR-based method using Promega markers. Concordance with MMR expression and factors associated with concordance were analyzed. In 2 colorectal cancer samples, MMR IHC failed due to inadequate staining conditions. In the remaining 516 cancers, a high level of MSI (MSI-H) was identified in 113 cases, and dMMR was identified in 112. The concordance of MSI and MMR IHC was 98.3%. Only 9 cases (4 pancreatobiliary, 3 colorectal, and 2 endometrial cancers) were discordant. Of the 113 MSI-H cases, 4 (3.5%) were proficient MMR (pMMR); of the 403 microsatellite stability (MSS) cases, 5 (1.2%) were dMMR. The independent factors associated with MSI-H/dMMR included meeting Amsterdam II criteria, assay purpose, and sampling method. Multivariate analysis revealed that cancer type (gastrointestinal cancers or others) was associated with concordance of MSI and MMR IHC. Three LS cases with pancreatic or endometrial cancer demonstrated MSS and dMMR, and one biliary cancer showed MSI-H and pMMR. Discordance between MSI and MMR IHC occasionally occurs in pancreaticobiliary and endometrial cancers. When suspected, both MSI and MMR IHC should be done to judge the ICI indication and screen for LS.
微卫星不稳定性(MSI)和错配修复缺陷(dMMR)是预测免疫检查点抑制剂(ICI)疗效和筛查林奇综合征(LS)的关键标志物。本研究调查了人类癌症中MSI与错配修复(MMR)一致性的发生率及相关因素。共对518份福尔马林固定的癌组织进行了MSI和MMR免疫组织化学(IHC)分析。采用Promega标记物通过基于聚合酶链反应(PCR)的方法分析MSI。分析了与MMR表达的一致性及相关因素。在2份结直肠癌样本中,由于染色条件不足,MMR IHC检测失败。在其余516例癌症中,113例检测到高水平微卫星不稳定性(MSI-H),112例检测到dMMR。MSI与MMR IHC的一致性为98.3%。仅9例(4例胰胆管癌、3例结直肠癌和2例子宫内膜癌)不一致。在113例MSI-H病例中,4例(3.5%)为错配修复功能正常(pMMR);在403例微卫星稳定(MSS)病例中,5例(1.2%)为dMMR。与MSI-H/dMMR相关的独立因素包括符合阿姆斯特丹Ⅱ标准、检测目的和取样方法。多因素分析显示,癌症类型(胃肠道癌或其他癌症)与MSI和MMR IHC的一致性相关。3例患有胰腺癌或子宫内膜癌的LS病例表现为MSS和dMMR,1例胆管癌表现为MSI-H和pMMR。MSI与MMR IHC之间的不一致偶尔发生在胰胆管癌和子宫内膜癌中。如有怀疑,应同时进行MSI和MMR IHC检测,以判断ICI适应证并筛查LS。